Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer - 19/08/11
, Thomas C. Krivak, MD b, Amanda Nickles Fader, MD c, Robert L. Coleman, MD d
Reprints: Thomas J. Herzog, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 161 Fort Washington Ave., 8th Floor, New York, NY 10032Résumé |
Objective |
We sought to determine the association between tumor responses in vitro to platinum therapy by using the ChemoFx drug response marker and overall survival (OS) after first-line platinum-based chemotherapy in patients with advanced-stage primary ovarian cancer (POC).
Study Design |
Chemosensitivity testing was performed in vitro on tumors from 192 POC patients. Tumors were classified as responsive, intermediately responsive, and nonresponsive to chemotherapy. Physicians made all management decisions. Survival status was retrieved from the Social Security Death Index. OS was modeled using Cox proportional hazard regression analysis.
Results |
Median OS was 72.5 months for patients with tumors categorized as responsive, 48.6 months for intermediately responsive, and 28.2 months for nonresponsive (P = .03; hazard ratio, 0.70; 95% confidence interval, 0.50–0.97). The ChemoFx prediction of responses to platinum agents was an independent predictor of OS.
Conclusion |
Results of chemosensitivity testing with a drug response marker for therapy was predictive of OS in POC patients.
Le texte complet de cet article est disponible en PDF.Key words : chemotherapy drug response marker, in vitro chemosensitivity testing, ovarian cancer, platinum-based chemotherapy
Plan
| This study was supported by Precision Therapeutics Inc, Pittsburgh, PA. |
|
| Dr Krivak is a member of the speaker's bureau of Precision Therapeutics Inc. Drs Coleman and Herzog have served as consultants for Precision Therapeutics Inc. |
|
| Cite this article as: Herzog TJ, Krivak TC, Fader AN, et al. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010;203:68.e1-6. |
Vol 203 - N° 1
P. 68.e1-68.e6 - juillet 2010 Retour au numéro
Article précédent
- Stromal cell–specific apoptotic and antiestrogenic mechanisms may explain uterine defects in humans after clomiphene citrate therapy
- Magdalena Nutu, Yi Feng, Emil Egecioglu, Birgitta Weijdegård, Elisabet Stener-Victorin, Ruijin Shao
- A systematic literature review of vitamin D and ovarian cancer
- Linda S. Cook, Heather K. Neilson, Diane L. Lorenzetti, Robert C. Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?